New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 11, 2014
18:01 EDTICPTNIH says patients on Intercept drug had more 'bad' cholesterol, WSJ says
Late Friday, the Wall Street Journal reported that the National Institutes of Health, NIH, said patients that were treated with Intercept Pharmaceuticals's experimental liver-disease drug obeticholic acid, or OCA, in a clinical trial experienced more abnormal cholesterol levels than those who were given a placebo. The NIH, said it was making this information available to give "broader context for the findings" of the trial, added the Wall Street Journal. Shares of Intercept traded down 6% in after-hours trading on Friday evening after the report. Reference Link
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
08:59 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
April 12, 2014
20:04 EDTICPTIntercept reports additional positive data from POISE trial at EASL
Subscribe for More Information
April 11, 2014
09:08 EDTICPTIntercept announces OCA preclinical study data
Subscribe for More Information
April 9, 2014
07:23 EDTICPTEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
April 8, 2014
11:03 EDTICPTPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
April 4, 2014
10:11 EDTICPTIntercept to present on POISE trial at EASL meeting
Subscribe for More Information
06:02 EDTICPTIntercept 1M share Secondary priced at $320.00
BofA/Merrill, Citigroup and Goldman acted as joint book running managers for the offering.
April 3, 2014
16:13 EDTICPTSAC Capital lowers passive stake in Intercept to less than 0.1% from 7.1%
April 2, 2014
09:18 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use